David Southwell. TScan

No­var­tis backs Har­vard spin­out's quest to build TCR repos­i­to­ry in $48M round

As T cell re­cep­tors emerged as a po­tent tool for the im­mune sys­tem to latch on­to tu­mor anti­gens, Stephen Elledge want­ed to screen anti­gen-TCR match­es in a faster, more sys­tem­at­ic way — one that would go be­yond cur­rent­ly known tar­gets but stop short of the new realms of neoanti­gens bioin­for­mat­ic pre­dic­tions.

Stephen Elledge

So the Har­vard pro­fes­sor spent the last 7 years con­sol­i­dat­ing new tech to come up with a plat­form that can run mul­ti­ple TCRs against anti­gen epi­topes and pin­point the ex­act pairs that ap­pear to in­ter­act. There’s al­so a built-in li­brary of the hu­man pep­tidome to flag any off-tar­get ef­fects and pre­vent safe­ty scares down the road.

What start­ed out on 96 plates in Elledge’s lab has now been scaled up and spun out to TScan Ther­a­peu­tics, which is now mak­ing its first pub­lic ap­pear­ance with $48 mil­lion in to­tal Se­ries A and B fund­ing.

The in­ter­est from No­var­tis In­sti­tutes for Bio­Med­ical Re­search was a key im­pe­tus for the round, CEO David South­well told me. The phar­ma gi­ant’s ven­ture arm al­so joined along­side Besse­mer, GV and Long­wood Fund.

“The whole goal is sort of to do it dif­fer­ent­ly than the way every­one else is do­ing it,” he said, which al­so ex­plained why he jumped on board last Oc­to­ber af­ter merg­ing In­otek with Rock­et.

One of Elledge’s big break­throughs here, South­well said, is de­vel­op­ing a unique flu­o­res­cent de­tec­tor sys­tem to find the prover­bial nee­dle in the haystack.

“It’s long been known as what hap­pens when a cy­to­tox­ic T cell meets an anti­gen is that it puts out com­pounds like per­forin, which put holes in the tu­mor cells, and granzyme B, which is a mes­sen­ger that is es­sen­tial­ly a cy­tokine which tells a cell to die. So that’s been known,” he said. “The ques­tion is how do you ac­tu­al­ly mea­sure the ac­tu­al killing ac­tiv­i­ty be­tween the cy­to­tox­ic T cell and a tar­get?”

The abil­i­ty to sort that all out on the fly means TScan can run a high-through­put, whole-genome search for nov­el anti­gens and the T cell re­cep­tors that may tar­get them.

There are many paths to go down with a plat­form as broad as this, and South­well read­i­ly ad­mits he’s yet to make up his mind as to whether TScan will opt for plat­form li­cens­ing or keep more of the de­vel­op­ment pro­grams to it­self. But the mon­ey they have is more than enough for a team of 20 sci­en­tists — many scooped from promi­nent biotechs like Ed­i­tas, CRISPR, KSQ and Juno — do­ing dis­cov­ery work.

The plat­form “is so broad that we could do a num­ber of phar­ma part­ner­ships that are dif­fer­ent in their scope, they don’t com­pete with each oth­er, and they leave us open to de­vel­op what we want, which is a repos­i­to­ry of TCR anti­gen pairs that work in both sol­id and liq­uid tu­mors,” he said.

Be­fore ar­riv­ing at that al­lo­gene­ic fu­ture, though, TScan has a tight time­line to ex­e­cute on au­tol­o­gous projects. The goal is to have two lead can­di­dates with­in 6 to 9 months and go in­to 2021 with a cou­ple of INDs.

Much of that will be con­duct­ed in a new site at Waltham, Mass­a­chu­setts, which will of­fer a key com­po­nent that their cur­rent digs at Har­vard Med­ical School lack: GMP man­u­fac­tur­ing fa­cil­i­ties.

“One of the biggest mis­takes that cell ther­a­py com­pa­nies make is hav­ing a plat­form like this and then you find a lead, and you’re re­al­ly ex­cit­ed about your lead, and you haven’t fig­ured out how to man­u­fac­ture it,” he said.

He’s re­cruit­ed Ken LeClair out of Ed­i­tas to run that op­er­a­tion. Gavin MacBeath, a sci­en­tif­ic founder of Mer­ri­mack, is CSO; Am­gen vet Hen­ry Rath is han­dling all the phar­ma in­ter­est as CBO; and Robert Crane is CFO.

The Big Phar­ma dis­card pile; Lay­offs all around while some biotechs bid farewell; New Roche CEO as­sem­bles top team; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

With earnings seasons in full swing, we’ve listened in on all the calls so you don’t have to. But news is popping up from all corners, so make sure you check out our other updates, too.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Raymond Stevens, Structure Therapeutics CEO

Be­hind Fri­day's $161M IPO: A star sci­en­tist, GPCR drug dis­cov­ery and a plan to chal­lenge phar­ma in di­a­betes

What does it take to pull off a $161 million biotech IPO these days?

In Structure Therapeutics’ case, it means having a star scientist co-founder paired with the computational drug discovery company Schrödinger, $198 million in private funding from blue-chip investors, almost six years of research work on G protein-coupled receptors and a slate of oral, small-molecule drugs, with an eye on the huge and growing diabetes and weight-loss market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Sen. Ron Wyden (D-OR) (Francis Chung/E&E News/Politico via AP Images)

In­fla­tion re­bates in­com­ing: Wyden calls on CMS to move quick­ly as No­var­tis CEO pledges re­ver­sal

Senate Finance Chair Ron Wyden (D-OR) this week sent a letter to the head of the Centers for Medicare & Medicaid Services seeking an update on how and when new inflation-linked rebates will take effect for drugs that see major price spikes.

The newly signed Inflation Reduction Act requires manufacturers to pay a rebate to Medicare when they increase drug prices faster than the rate of inflation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Trodelvy notch­es a win in most com­mon form of breast can­cer

Following a promise last year to go “big and fast in breast cancer,” Gilead has secured a win for Trodelvy in the most common form.

The drug was approved to treat HR-positive, HER2-negative breast cancer patients who’ve already received endocrine-based therapy and at least two other systemic therapies for metastatic cancer, Gilead announced on Friday.

Trodelvy won its first indication in metastatic triple-negative breast cancer back in 2020, and has since added urothelial cancer to the list. HR-positive HER2-negative breast cancer accounts for roughly 70% of new breast cancer cases worldwide per year, according to senior VP of oncology clinical development Bill Grossman, and many patients develop resistance to endocrine-based therapies or worsen on chemotherapy.

Af­ter 13 years, Ramy Mah­moud steps in­to CEO seat at Opti­nose; Ru­pert Vessey set to ex­it Bris­tol My­ers in Ju­ly

After 13 years as president and COO at Optinose, Ramy Mahmoud has stepped into a new role as its CEO. He is taking the place of Peter Miller, who stepped down earlier this week, though Miller is still staying with the company as a consultant.

In 2010, the two business partners joined Optinose to take it in a new direction, transforming it from a delivery platform to product company. They previously worked together at Johnson & Johnson, when Miller was president at Janssen and Mahmoud headed medical affairs. Miller said after he learned about Optinose, “I did what I always do, which is find people smarter than me to talk with about the idea. And the first person I called was Ramy … and I said, ‘Hey, Ramy, what do you think of this technology?’”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Ma­gen­ta halts stem cell work and may sell it­self fol­low­ing pa­tient death, clin­i­cal hold

Magenta Therapeutics said it is halting work on its stem cell transplant drug pipeline and may sell itself, a week after the company reported the death of a patient in an early stage trial of its antibody-drug conjugate.

The Cambridge, MA-based company said it will conduct a “review of strategic alternatives,” and that could include an “acquisition, merger, business combination, or other transaction.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Te­va drops out of in­dus­try trade group PhRMA

Following in AbbVie’s footsteps, Teva confirmed on Friday that it’s dropping out of the industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA).

Teva didn’t give a reason for its decision to leave, saying only in a statement to Endpoints News that it annually reviews “effectiveness and value of engagements, consultants and memberships to ensure our investments are properly seated.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)

Sanofi sees downtick in flu sales as it preps for launch of RSV an­ti­body

Sanofi expects its RSV antibody jointly developed with AstraZeneca will be available next season, executive VP of vaccines Thomas Triomphe announced on the company’s quarterly call.

Beyfortus, also known as nirsevimab, was approved in the EU back in November and is currently under FDA review with an expected decision coming in the third quarter of this year. The news comes as the FDA plans to hold advisory committee meetings over the next couple months to review RSV vaccines from Pfizer and GSK.

Christophe Weber, Takeda CEO (Photographer: Shoko Takayasu/Bloomberg via Getty Images)

Take­da fo­cus­es on ‘di­verse’ pipeline prospects on heels of two ac­qui­si­tions

After a whopping $4 billion asset buy from Nimbus Therapeutics, along with a $400 million deal with Hutchmed for a colorectal cancer drug, Takeda executives touted pipeline optimism on its latest earnings call this week.

That’s because the TYK2 inhibitor for psoriasis Takeda is getting from Nimbus, along with the Hutchmed fruquintinib commercialization outside of China, are just two of what it reports are 10 late-stage development programs of promising candidates.